Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 13/20 | 0.52 |
| ▸ | PIK3CD | O00329 | 7/20 | 0.52 |
| ▸ | PIK3CB | P42338 | 7/20 | 0.52 |
| ▸ | PIK3CG | P48736 | 6/20 | 0.52 |
| ▸ | CDK4 | P11802 | 6/20 | 0.41 |
| ▸ | CDK2 | P24941 | 6/20 | 0.41 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.41 |
| ▸ | PLK1 | P53350 | 2/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | AURKA | O14965 | 2/20 | 0.35 |
| ▸ | CDK7 | P50613 | 2/20 | 0.35 |
| ▸ | CDK9 | P50750 | 2/20 | 0.35 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.35 |
| ▸ | CDK1 | P06493 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3664160 | 0.95 | PIK3CA (0.58) | PIK3CAPIK3CDPIK3CBPIK3CGCDK4 | |
| SCHEMBL3233602 | 0.85 | PIK3CA (0.42) | PIK3CAPIK3CDPIK3CBPIK3CGCDK4 | |
| SCHEMBL29011726 | 0.82 | PIK3CA (0.52) | PIK3CAPIK3CDPIK3CBPIK3CGCDK4 | |
| SCHEMBL3661249 | 0.81 | KDM4E (0.49) | PIK3CAPIK3CDPIK3CBPIK3CGCDK4 | |
| SCHEMBL1939694 | 0.80 | CDK4 (0.50) | PIK3CAPIK3CDPIK3CBPIK3CGCDK4 | |
| SCHEMBL3231028 | 0.80 | PIK3CA (0.56) | PIK3CAPIK3CDPIK3CBPIK3CGCDK4 | |
| SCHEMBL3232973 | 0.79 | PIK3CA (0.55) | PIK3CAPIK3CDPIK3CBPIK3CGCDK4 | |
| SCHEMBL1884399 | 0.78 | PIK3CG (0.61) | PIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL3237122 | 0.77 | PIK3CA (0.52) | PIK3CAPIK3CDPIK3CBPIK3CGCDK4 | |
| SCHEMBL3232487 | 0.77 | PIK3CA (0.51) | PIK3CAPIK3CDPIK3CBPIK3CGCDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8940771-B2 | Organic compounds | NOVARTIS AG (CH) | 2015-01-27 | — | — | US | disclosed |
| EP-2240475-B1 | THIAZOLE DERIVATIVES USED AS PI 3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2013-09-25 | — | — | EP | disclosed |
| EP-2240475-A1 | THIAZOLE DERIVATIVES USED AS PI 3 KINASE INHIBITORS | Novartis AG (CH) | 2010-10-20 | — | — | EP | disclosed |
| WO-2009080694-A1 | THIAZOLE DERIVATIVES USED AS PI 3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-07-02 | — | — | WO | disclosed |
| US-20090163469-A1 | Organic Compounds | NOVARTIS AG | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163469-A1 | Organic Compounds | PIK3C3, PIK3CA, PIK3CD | PIK3CA 2/4885PIK3CD 3/4885PIK3CB 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.